Courageous. Focused. Passionate.

Harnessing the Power of Nature With Precision Science™

Cancer continues to inflict devastating consequences worldwide. Bexion is committed to conquering cancer and to deliver on our commitment, we have assembled a world class leadership team to advance our innovative, targeted cancer therapy platform. Targeted therapy brings significant potential to the fight against cancer and we are relentless in our pursuit to realize this potential.

banner-info
Home2020-01-20T09:17:26-05:00

– Our Platform

An innovative, targeted approach to treating cancer

Our treatment specifically targets unique features of cancer cells, including externalized phosphatidylserine and tumor cell lysosomes by utilizing a small lysosomal protein known as Saposin C.

Learn More

– Our Pipeline

A Pipeline-in-a-Product asset with potential for multiple indications

BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.

Learn More

– clinical trials

Update

Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.

Learn More

Resources

Bexion Resources

Resources

Learn More
View All Resources

News

    Press Release

    Bexion Pharmaceuticals, Inc. to Present Clinical and Pre-Clinical Data at 2020 SNO Annual Meeting

    September 16, 2020

    FOR IMMEDIATE RELEASE [Covington, KY: September 16, 2020] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cures for cancer announced today it will present clinical and pre-clinical electronic posters with audio presentations at the Society of Neuro-Oncology (SNO) annual virtual conference to be held November 19-21, 2020. "We ... Read More

      Press Release

      Bexion Pharmaceuticals Presenting BXQ-350 Data at ASCO 2020

      May 13, 2020

      For Immediate Release, Covington, KY May 13, 2020 Bexion Pharmaceuticals announced today that the following three abstracts submitted to the 2020 American Society of Clinical Oncology (ASCO) have been accepted for oral or poster presentation: Oral Presentation Tolerability and preliminary efficacy of BXQ-350 for refractory solid tumors and high-grade gliomas: First-in-human, first-in-class phase I trial. ... Read More

      View All Media